Modern Pediatrics. Ukraine. (2026).1(153): 40-50. doi: 10.15574/SP.2026.1(153).4050
Мокія-Сербіна С. О., Шелевицька В. А.
Дніпровський державний медичний університет, Україна

Для цитування: Мокія-Сербіна СО, Шелевицька ВА. (2025). Мікоплазмова пневмонія у дітей: сучасні аспекти діагностування і лікування. Сучасна педіатрія. Україна. 1(153): 40-50. doi: 10.15574/SP.2026.1(153).4050.
Стаття надійшла до редакції 18.11.2025 р., прийнята до друку 08.02.2026 р.

Стаття присвячена актуальній проблемі педіатрії й інфектології – мікоплазмовій пневмонії. Захворювання трапляється в дітей різного віку, але найчастіше у віковій категорії 5-9 років, становить 4-40% випадків позалікарняної пневмонії в дітей. Поширеним є співіснування Mycoplasma pneumoniae з іншими інфекційними агентами – вірусами і бактеріями. Останній спалах мікоплазмової інфекції у світі розпочався наприкінці 2023 року. Інфекція характеризується тяжчим перебігом, уражує як дорослих, так і дітей. Значно зростає, особливо в країнах Східної Азії, рівень захворюваності на рефрактерну до макролідів мікоплазмову пневмонію.
Мета – на основі узагальнення даних літературних джерел науково-дослідницьких платформ «Scopus», «PubMed», «Web of Science», «Google Scholar» навести клініко-параклінічні особливості пневмонії, зумовленої Mycoplasma pneumoniae.
Описано особливості перебігу, підходи до діагностування і лікування рефрактерної до макролідів мікоплазмової пневмонії, рефрактерної мікоплазмової пневмонії, резистентної до кортикостероїдів мікоплазмової пневмонії, а також пневмонії, викликаної змішаною інфекцією. Схеми лікування наведено з урахуванням патогенезу захворювання, зумовленого не лише прямим впливом збудника, але й індукованою ним імунною відповіддю. Під час визначення рекомендацій взято до уваги вітчизняні клінічні настанови.
Висновки. Остаточне вирішення питання щодо діагнозу мікоплазмової пневмонії в дітей у кожному конкретному випадку має базуватися на сукупності даних анамнезу, клінічних ознак і симптомів, результатів допоміжних методів дослідження, що з високим ступенем вірогідності може забезпечити вибір оптимальної стартової терапії, прогнозувати перебіг захворювання і вирішити питання необхідності госпіталізації.
Автори заявляють про відсутність конфлікту інтересів.
Ключові слова: мікоплазмова пневмонія, діти, діагностування, лікування.

ЛІТЕРАТУРА

1. Al-Zaidi SA, MacGregor D, Mahant S, Richardson SE, Bitnun A. (2015). Neurological complications of PCR-proven M. pneumoniae infections in children: prodromal illness duration may reflect pathogenetic mechanisms. Clinical Infectious Diseases. 61(7): 1092-1098. https://doi.org/10.1093/cid/civ473; PMid:26084846

2. American Academy of Pediatrics. (2024). Tables of antibacterial drug dosages. In: Red Book: 2024-2027 Report of the Committee on Infectious Diseases, 33rd ed, Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics: 987.

3. Atkinson TP, Balish MF, Waites KB. (2008). Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS microbiology reviews. 32(6): 956-973. https://doi.org/10.1111/j.1574-6976.2008.00129.x; PMid:18754792

4. Bidell MR, Lodise TP. (2016). Fluoroquinolone‐associated tendinopathy: does levofloxacin pose the greatest risk?. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36(6): 679-693. https://doi.org/10.1002/phar.1761; PMid:27138564

5. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. (2014). Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 133(6): 1081-1090. https://doi.org/10.1542/peds.2013-3729; PMid:24864174

6. Bolormaa E, Park JY, Choe YJ, Kang CR, Choe SA, Mylonakis E. (2024). Treatment of Macrolide-resistant Mycoplasma pneumoniae Pneumonia in Children: A Meta-analysis of Macrolides Versus Tetracyclines. The Pediatric Infectious Disease Journal. 44(3): 200-206. https://doi.org/10.1097/INF.0000000000004568; PMid:39383346

7. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C et al. (2011). Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 53(7): e25-e76. https://doi.org/10.1093/cid/cir531; PMid:21880587 PMCid:PMC7107838

8. Centers for Disease Control and Prevention. (2024). Mycoplasma pneumoniae Infection Surveillance and Trends. URL: https://www.cdc.gov/mycoplasma/php/surveillance/index.html.

9. Chiu CY, Chen CJ, Wong KS, Tsai MH, Chiu CH, Huang YC. (2015). Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia. Journal of Microbiology, Immunology and Infection. 48(1): 51-56. https://doi.org/10.1016/j.jmii.2013.06.006; PMid:23927825

10. Cho HK. (2021). Consideration in treatment decisions for refractory Mycoplasma pneumoniae pneumonia. Clinical and Experimental Pediatrics. 64(9): 459. https://doi.org/10.3345/cep.2020.01305; PMid:33561337 PMCid:PMC8426095

11. Choi YJ, Chung EH, Lee E, Kim CH, Lee YJ, Kim HB et al. (2022). Clinical characteristics of macrolide-refractory Mycoplasma pneumoniae pneumonia in Korean children: a multicenter retrospective study. Journal of Clinical Medicine. 11; 2: 306. https://doi.org/10.3390/jcm11020306; PMid:35054002 PMCid:PMC8779611

12. Danner MT, Binns HC, Nguyen K, Johnson C, Dunn J, Niles D et al. (2024). Resurgence of pediatric Mycoplasma pneumoniae infections in Southeast Texas, Nov 2023-June 2024. Journal of the Pediatric Infectious Diseases Society. 14(1): piae119. https://doi.org/10.1093/jpids/piae119; PMid:39673412

13. Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM et al. (2016, Mar 30). Identification of bacterial and viral codetections with Mycoplasma pneumoniae using the TaqMan array card in patients hospitalized with community-acquired pneumonia. In Open forum infectious diseases. 3(2): ofw071. https://doi.org/10.1093/ofid/ofw071; PMid:27191004 PMCid:PMC4867659

14. Djukic S, Lukac M, Nikolic D, Radic S, Atanaskovic-Markovic M, Medjo B. (2014). Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Italian Journal of Pediatrics. 40: 104. URL: http://www.ijponline.net/content/40/1/104. https://doi.org/10.1186/s13052-014-0104-4; PMid:25518734 PMCid:PMC4279889

15. Edens C. (2024). Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024. MMWR. Morbidity and mortality weekly report: 73.

16. Espeleta-Fox A, García-Salido A, De Unzueta-Roch JL, Caro-Patón GDL, Moral-Larraz A, Toledano-Revenga J et al. (2025). Severe mycoplasma pneumoniae infections during the 2023-2024 outbreak: a single-center descriptive study in a pediatric intensive care. The Pediatric Infectious Disease Journal. 44(6): e225-e228. Epub 2025 Jan 10. https://doi.org/10.1097/INF.0000000000004734; PMid:40763306

17. Esposito S, Argentiero A, Gramegna A, Principi N. (2021). Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems. Expert Opinion on Pharmacotherapy. 22(9): 1193-1202. https://doi.org/10.1080/14656566.2021.1882420; PMid:33544008

18. Esposito S, Tagliabue C, Bosis S, Principi N. (2011). Levofloxacin for the treatment of Mycoplasma pneumoniae-associated meningoencephalitis in childhood. International journal of antimicrobial agents. 37(5): 472-475. https://doi.org/10.1016/j.ijantimicag.2011.01.008; PMid:21377335

19. FDA. (2018). Maryland: FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. URL: https://www.fda.gov/media/97602/download.

20. Gardiner SJ, Gavranich JB, Chang AB. (2015). Antibiotics for community‐acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database of Systematic Reviews. 1(1): CD004875. https://doi.org/10.1002/14651858.CD004875.pub5; PMid:25566754 PMCid:PMC10585423

21. Han MS, Yun KW, Lee HJ, Park JY, Rhie K, Lee et al. (2018). Contribution of Co-detected Respiratory Viruses and Patient Age to the Clinical Manifestations of Mycoplasma Pneumoniae Pneumonia in Children. Pediatr Infect Dis J. 37: 531. https://doi.org/10.1097/INF.0000000000001819; PMid:29095244

22. Hardy RD, Coalson JJ, Peters J, Chaparro A, Techasaensiri C, Cantwell AM et al. (2009). Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PloS one. 4(10): e7562. https://doi.org/10.1371/journal.pone.0007562; PMid:19859545 PMCid:PMC2762541

23. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M et al. (2011). British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 66; Suppl 2: ii1-ii23. https://doi.org/10.1136/thoraxjnl-2011-200598; PMid:21903691

24. Jackson MA, Schutze GE, Committee on Infectious Diseases. (2016). The use of systemic and topical fluoroquinolones. Pediatrics. 138(5): e20162706. https://doi.org/10.1542/peds.2016-2706; PMid:27940800

25. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed et al. (2015). Community-acquired pneumonia requiring hospitalization among US children. New England Journal of Medicine. 372(9): 835-845. https://doi.org/10.1056/NEJMoa1405870; PMid:25714161 PMCid:PMC4697461

26. Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. (2022). Global trends in the proportion of macrolide-resistant mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA network open. 5(7): e2220949-e2220949. https://doi.org/10.1001/jamanetworkopen.2022.20949; PMid:35816304 PMCid:PMC9274321

27. Kim Y, Park GW, Kim S, Moon HJ, Won S, Chung W et al. (2021). Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age – a nationwide retrospective cohort. Journal of Thoracic Disease. 13(6): 3399. https://doi.org/10.21037/jtd-20-2256; PMid:34277036 PMCid:PMC8264711

28. Kohno S, Ishida T, Izumikawa K, Iwata S, Kadota JH, Tanaka H. (2014). The Japanese Society of Mycoplasmology: guiding principles for treating Mycoplasma pneumoniae [Internet] URL: http://square.umin.ac.jp/jsm/shisin.pdf.

29. Kok HC, Chang AB, Fong SM, McCallum, GB, Yerkovich ST, Grimwood, K. (2025). Antibiotics for Paediatric Community-Acquired Pneumonia: What is the Optimal Course Duration?. Pediatric Drugs. 27(3): 261-272. https://doi.org/10.1007/s40272-024-00680-4; PMid:39847251 PMCid:PMC12031807

30. Krafft C, Christy C. (2020). Mycoplasma pneumonia in children and adolescents. Pediatrics in Review. 41(1): 12-19. https://doi.org/10.1542/pir.2018-0016; PMid:31894069

31. Kutty PK, Jain S, Taylor TH, Bramley AM, Diaz MH, Ampofo K et al. (2019). Mycoplasma pneumoniae among children hospitalized with communit y-acquired pneumonia. Clinical Infectious Diseases. 68(1): 5-12. https://doi.org/10.1093/cid/ciy419; PMid:29788037 PMCid:PMC6552676

32. Larcher R, Boudet A, Roger C, Villa F, Loubet, P. (2023). Mycoplasma pneumoniae is back! Is it the next pandemic? Anaesthesia Critical Care & Pain Medicine. 43(1): 101338. https://doi.org/10.1016/j.accpm.2023.101338; PMid:38072068

33. Li G, Zhou J, Gao N, Liu R, Shen J. (2025). Establishment of a rapid detection method for Mycoplasma pneumoniae based on RPA-CRISPR-Cas12a technology. Clinica Chimica Acta. 564: 119906. https://doi.org/10.1016/j.cca.2024.119906; PMid:39127296

34. Li J, Zhang H, Guo J, Ma X. (2024, Jan 16). Clinical features of Mycoplasma pneumoniae pneumonia in children without fever. BMC Pediatr. 24(1): 52. https://doi.org/10.1186/s12887-023-04512-1; PMid:38229052 PMCid:PMC10790524

35. Liu J, Bao B, Zhang T, Jia W, Guo C, Song. (2025). Comparative analysis of the clinical characteristics of severe Mycoplasma pneumoniae pneumonia and severe bacterial pneumonia in children. BMC Pediatr. 25(1): 439. https://doi.org/10.1186/s12887-025-05804-4; PMid:40448048 PMCid:PMC12125830

36. Liu J, He R, Wu R, Wang B, Xu H, Zhang Y et al. (2020). Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing Children's hospital. BMC infectious diseases. 20(1): 51. https://doi.org/10.1186/s12879-020-4774-9; PMid:31948402 PMCid:PMC6966865

37. Liu J, Zhao F, Lu J, Xu H, Liu H, Tang X et al. (2019). High Mycoplasma pneumoniae loads and persistent long-term Mycoplasma pneumoniae DNA in lower airway associated with severity of pediatric Mycoplasma pneumoniae pneumonia. BMC infectious diseases. 19(1): 1045. https://doi.org/10.1186/s12879-019-4667-y; PMid:31823740 PMCid:PMC6905005

38. Liu TY, Lee WJ, Tsai CM, Kuo KC, Lee CH, Hsieh KS et al. (2018). Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children. Pediatrics & Neonatology. 59(5): 501-506. https://doi.org/10.1016/j.pedneo.2017.12.008; PMid:29337082

39. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D et al. (2010). Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagnostic microbiology and infectious disease. 67(4): 355-358. https://doi.org/10.1016/j.diagmicrobio.2010.03.004; PMid:20638604

40. Loconsole D, De Robertis AL, Sallustio A, Centrone F, Morcavallo C, Campanella S et al. (2021). Update on the epidemiology of macrolide-resistant Mycoplasma pneumoniae in Europe: a systematic review. Infectious Disease Reports. 13(3): 811-820. https://doi.org/10.3390/idr13030073; PMid:34562998 PMCid:PMC8482213

41. Loens K, Ieven M. (2016). Mycoplasma pneumoniae: current knowledge on nucleic acid amplification techniques and serological diagnostics. Frontiers in microbiology. 7: 448. https://doi.org/10.3389/fmicb.2016.00448; PMid:27064893 PMCid:PMC4814781

42. Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F et al. (2014). Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatric pulmonology. 49(4): 377-380. https://doi.org/10.1002/ppul.22752; PMid:23401275

43. Meyer Sauteur PM, Pánisová E, Bachmann LM, Ambroggio L, Berger C. (2020). Evaluation of IgM lateral flow assay as a screening tool for Mycoplasma pneumoniae infection in childhood pneumonia. Journal of clinical microbiology, 58(11), 10-1128. https://doi.org/10.1128/JCM.01498-20; PMid:32878949 PMCid:PMC7587085

44. Meyer Sauteur PM, Seiler M, Tilen R, Osuna E, von Wantoch M, Sidorov S et al. (2024). A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study. Trials. 25(1): 655. https://doi.org/10.1186/s13063-024-08438-6; PMid:39363201 PMCid:PMC11450998

45. Meyer Sauteur PM, Trück J, van Rossum AM, Berger C. (2020). Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. The Journal of infectious diseases. 222(1): 136-147. https://doi.org/10.1093/infdis/jiaa062; PMid:32034406

46. Ministry of Health of Ukraine; State Expert Center of the Ministry of Health of Ukraine; Association of Pediatrics of Ukraine. (2022). Pneumonia in children: evidence based clinical guidelines. Kyiv: 61. URI: https://www.dec.gov.ua/wp-content/uploads/2022/08/2022_1380_kn_pnevmoniyi_u_ditej.pdf.

47. Miyashita N, Akaike H, Teranishi H, Nakano T, Ouchi K, Okimoto N. (2014). Chest computed tomography for the diagnosis of Mycoplasma pneumoniae infection. Respirology. 19(1): 144-145. https://doi.org/10.1111/resp.12218; PMid:25219424

48. Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H et al. (2015). Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. Journal of Infection and Chemotherapy. 21(3): 153-160. https://doi.org/10.1016/j.jiac.2014.10.008; PMid:25533771

49. Miyashita N, Sugiu T, Kawai Y, Oda K, Yamaguchi T, Ouchi K et al. (2009). Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. BMC Medical Imaging. 9: 1-8. URL: http://www.biomedcentral.com/1471-2342/9/7. https://doi.org/10.1186/1471-2342-9-7; PMid:19400968 PMCid:PMC2680832

50. Nagoba BS, Dhotre SV, Gavkare AM, Mumbre SS, Dhotre PS. (2024). Understanding serum inflammatory markers in pediatric Mycoplasma pneumoniae pneumonia. World Journal of Clinical Pediatrics. 13(4): 98809. https://doi.org/10.5409/wjcp.v13.i4.98809; PMid:39654670 PMCid:PMC11572613

51. Narita M. (2016). Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis. Frontiers in microbiology. 7: 23. https://doi.org/10.3389/fmicb.2016.00023; PMid:26858701 PMCid:PMC4729911

52. Nilsson AC, Björkman P, Welinder-Olsson C, Widell A, Persson K. (2010). Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. BMC infectious diseases. 10: 1-8. https://doi.org/10.1186/1471-2334-10-39; PMid:20184731 PMCid:PMC2837002

53. Onozuka D, Chaves LF. (2014). Climate variability and nonstationary dynamics of Mycoplasma pneumoniae pneumonia in Japan. PLoS One. 9(4): e95447. https://doi.org/10.1371/journal.pone.0095447; PMid:24740102 PMCid:PMC3989333

54. Островський ММ, Варунків ОІ. (2015) Стратегія використання азитроміцину та кларитроміцину в пульмонологічній практиці. Здоров’я України: 25-26. URL: https://health-ua.com/newspaper/med_gaz_zu/21078-medichna-gazeta-zdorovya-ukrani–2-351-schen-2015-pwww.

55. Raghuram A, Furmanek S, Chandler T, Rashid S, Mattingly W, Ramirez J. (2025). Description of a Current Outbreak of Mycoplasma pneumoniae in the United States. Pathogens. 14(1): 60. https://doi.org/10.3390/pathogens14010060; PMid:39861021 PMCid:PMC11768315

56. Sauteur PMM, Beeton ML, Pereyre S, Bébéar C, Gardette M, Hénin N et al. (2024). Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. The Lancet Microbe. 5(2): e100-e101. https://doi.org/10.1016/ S2666-5247(23)00344-0.

57. Sauteur PMM, Unger WW, van Rossum AM, Berger, C. (2018). The art and science of diagnosing Mycoplasma pneumoniae infection. The Pediatric infectious disease journal. 37(11): 1192-1195. https://doi.org/10.1097/INF.0000000000002171; PMid:30169485

58. Spuesens EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van Adrichem LN et al. (2013). Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS medicine. 10(5): e1001444. https://doi.org/10.1371/journal.pmed.1001444; PMid:23690754 PMCid:PMC3653782

59. Su DQ, Li JF, Zhuo ZQ. (2020). Clinical analysis of 122 cases with mycoplasma pneumonia complicated with atelectasis: a retrospective study. Advances in Therapy. 37: 265-271. https://doi.org/10.1007/s12325-019-01129-8; PMid:31707714

60. Sun LL, Ye C, Zhou YL, Zuo SR, Deng ZZ, Wang CJ. (2020). Meta-analysis of the clinical efficacy and safety of high-and low-dose methylprednisolone in the treatment of children with severe Mycoplasma pneumoniae pneumonia. The Pediatric Infectious Disease Journal. 39(3): 177-183. https://doi.org/10.1097/INF.0000000000002529; PMid:31738328

61. Tong L, Huang S, Zheng C, Zhang Y, Chen Z. (2022). Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management. Journal of Clinical Medicine. 11(10): 2824. https://doi.org/10.3390/jcm11102824; PMid:35628949 PMCid:PMC9144103

62. Tsai TA, Tsai CK, Kuo KC, Yu HR. (2021). Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. Journal of Microbiology, Immunology and Infection, 54(4): 557-565. https://doi.org/10.1016/j.jmii.2020.10.002; PMid:33268306 PMCid:PMC10704248

63. Tuo W, Guo X, Wu M, Xie S, Shen X et al. (2023). Application value of antibody titres and RNA detection in the early prediction of Mycoplasma pneumoniae pneumonia in children: a retrospective study. BMC Infectious Diseases. 23(1): 220. https://doi.org/10.1186/s12879-023-08161-8; PMid:37029345 PMCid:PMC10082536

64. Waites KB, Ratliff A, Crabb DM, Xiao L, Qin X, Selvarangan R et al. (2019). Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. Journal of clinical microbiology. 57(11): 10-1128. https://doi.org/10.1128/JCM.00968-19; PMid:31484701 PMCid:PMC6813023

65. Waites KB, Talkington DF. (2004). Mycoplasma pneumoniae and its role as a human pathogen. Clinical microbiology reviews. 17(4): 697-728. https://doi.org/10.1128/CMR.17.4.697-728.2004; PMid:15489344 PMCid:PMC523564

66. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. (2017). Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 30: 747-809. https://doi.org/10.1128/CMR.00114-16; PMid:28539503 PMCid:PMC5475226

67. Wang J, Xia C, Sharma A, Gaba GS, Shabaz M. (2021). Chest CT findings and differential diagnosis of mycoplasma pneumoniae pneumoniae and mycoplasma pneumoniae combined with streptococcal pneumonia in children. Journal of Healthcare Engineering. 2021(1): 8085530. https://doi.org/10.1155/2021/8085530; PMid:34221302 PMCid:PMC8219438

68. Wang LP, Hu ZH, Jiang JS, Jin J. (2024). Serum inflammatory markers in children with Mycoplasma pneumoniae pneumonia and their predictive value for mycoplasma severity. World Journal of Clinical Cases. 12(22): 4940. https://doi.org/10.12998/wjcc.v12.i22.4940; PMid:39109035 PMCid:PMC11238786

69. World Health Organization (2023, Nov 23). Disease outbreak news; upsurge of respiratory illnesses among children in northern China. URL: https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON494.

70. World Health Organization. (2024, Dec 23). The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization 2022. URL: https://www.who.int/publications/i/item/9789240062382.

71. Yamazaki T, Kenri T. (2016). Epidemiology of Mycoplasm pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Frontiers in microbiology. 7: 693. https://doi.org/10.3389/fmicb.2016.00693

72. Yan C, Xue G, Zhao H, Feng Y, Li S, Cui J et al. (2019). Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children. 54(7): 1012-1021. Epub 2019 May 22. https://doi.org/10.1002/ppul.24327; PMid:31119869

73. Yang EA, Kang HM, Rhim JW, Kang JH, Lee KY. (2019). Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. Journal of Clinical Medicine. 8(5): 726. https://doi.org/10.3390/jcm8050726; PMid:31121867 PMCid:PMC6572103

74. Yang HJ, Song DJ, Shim JY. (2017). Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Korean journal of pediatric. 60(6): 167-174. Epub 2017 Jun 22. https://doi.org/10.3345/kjp.2017.60.6.167; PMid:28690643 PMCid:PMC5500384

75. Yang S, Liu X, Han Y, Wang H, Mei Y, Wang H et al. (2025). Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases. 44(6): 1505-1522. https://doi.org/10.1007/s10096-025-05101-z; PMid:40106136

76. Yan Y, Wei Y, Jiang W, Hao C. (2016). The clinical characteristics of corticosteroid-resistant refractory Mycoplasma Pneumoniae pneumonia in children. Scientific reports. 6(1): 39929. https://doi.org/10.1038/srep39929; PMid:28008989 PMCid:PMC5180238

77. Yoon IA, Hong KB, Lee HJ, Yun KW, Park JY, Choi YH et al. (2017). Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycop lasma pneumoniae pneumonia. BMC infectious diseases. 17(1): 402. https://doi.org/10.1186/s12879-017-2500-z; PMid:28592263 PMCid:PMC5463359

78. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH et al. (2010, Jul 6). Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr. 10: 48. https://doi.org/10.1186/1471-2431-10-48; PMid:20604923 PMCid:PMC2910686

79. Youn YS, Lee KY. (2012). Mycoplasma pneumoniae pneumonia in children. Korean journal of pediatrics. 55(2): 42. https://doi.org/10.3345/kjp.2012.55.2.42; PMid:22375148 PMCid:PMC3286761

80. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. (2014, Jan). Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children. Allergy Asthma Immunol Res. 6(1): 22-26. Epub 2013 Nov 15. https://doi.org/10.4168/aair.2014.6.1.22; PMid:24404389 PMCid:PMC3881395

81. Yun KW, Wallihan R, Desai A, Alter S, Ambroggio L, Cohen DM et al (2022). Clinical characteristics and etiology of community-acquired pneumonia in US children, 2015-2018. The Pediatric infectious disease journal. 41(5): 381-387. https://doi.org/10.1097/INF.0000000000003475; PMid:35143427

82. Yusuf SO, Chen P. (2023). Clinical characteristics of community-acquired pneumonia in children caused by mycoplasma pneumoniae with or without myocardial damage: A single-center retrospective study. World Journal of Clinical Pediatrics. 12(3): 115. https://doi.org/10.5409/wjcp.v12.i3.115; PMid:37342450 PMCid:PMC10278075

83. Zhang X, Chen Z, Gu W, Ji W, Wang Y, Hao C et al (2018). Viral and bacterial co-infection in hospitalized children with refractory Mycoplasma pneumoniae pneumonia. Epidemiology & Infection. 146(11): 1384-1388. https://doi.org/10.1017/S0950268818000778; PMid:29970200 PMCid:PMC9133674

84. Zhang X, Sun R, Jia W, Li P, Song C. (2024). Clinical characteristics of lung consolidation with Mycoplasma pneumoniae pneumonia and risk factors for Mycoplasma pneumoniae necrotizing pneumonia in children. Infectious Diseases and Therapy. 13(2): 329-343. https://doi.org/10.1007/s40121-023-00914-x; PMid:38265626 PMCid:PMC10904708

85. Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. (2016). The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PloS one. 11(5): e0156465. https://doi.org/10.1371/journal.pone.0156465; PMid:27227519 PMCid:PMC4882022

86. Zhou J, Xiao F, Fu J, Jia N, Huang X, Sun C et al. (2025). A one-pot, one-step CRISPR platform (CRISPR-one) for nucleic acid detection: Application for the detection of Mycoplasma pneumoniae. Sensors and Actuators B: Chemical. 422: 136600. https://doi.org/10.1016/j.snb.2024.136600